The strategy to have “in-country, for country” manufacturing and diversified supply chains, has helped Agilent Technologies Inc, said an executive with the US-based scientific tools company, at a time ...

Agilent LC/MS systems and software are designed for robustness, ease of use, and consistent performance, helping labs ensure higher productivity and lower operating costs. Integrating seamlessly with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Bay Area laboratory solutions company Agilent Technologies has agreed to acquire Biocare Medical, a pathology solutions business, in an all-cash transaction valued at $950 million. Agilent aims to ...

Agilent Technologies acquires Biocare Medical for $950M to expand into high-growth pathology and cancer diagnostics, enhancing recurring consumables revenue streams. Agilent trades below historical ...

Expands Agilent’s pathology portfolio through addition of highly complementary antibody, reagent and instrument business with annual double-digit revenue and profit growth since 2021 Expected to be ...

Agilent Technologies said Monday it agreed to acquire Biocare Medical for $950 million in cash to expand its pathology portfolio. Biocare’s antibody, reagent and instrument business complements ...

Agilent Technologies Inc. agreed to acquire privately held Biocare Medical, which makes instruments and materials used in cancer research, in an all-cash transaction valued at $950 million. Biocare ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

日复一日持续稳定运行的液相色谱平台值得您的信赖。Agilent1260InfinityII液相色谱系统为您提供zui广泛的仪器选择,*的操作效率，使您对结果更有信心一任无穷幻变，自稳固于心。 可靠的仪器将新色谱柱技术与*的备件相结合,可保证稳定的分离和检测 性能,使您对 ...

Agilent Technologies President and CEO Padraig McDonnell joins 'Mad Money' host Jim Cramer to talk quarterly results, where it is seeing growth opportunities, the type of research it is supporting and ...